top of page

Sepsis & Septic Shock

Public·389 members

Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial - The Lancet Respiratory Medicine

The PROPHY-VAP study, a multicenter, randomized trial in eight French hospitals, evaluated the efficacy of a single dose of ceftriaxone in preventing early ventilator-associated pneumonia (VAP) in 319 mechanically ventilated, comatose patients with acute brain injury. Patients were assigned to either ceftriaxone or placebo groups. The study found a significant reduction in early VAP incidence in the ceftriaxone group (14%) compared to the placebo group (32%), with no adverse effects. This led to the recommendation of including ceftriaxone in VAP prevention protocols for such patients.

Ibrahim Ameen
Fahd Yahya  Yahya
Couldn’t Load Comments
It looks like there was a technical problem. Try reconnecting or refreshing the page.
bottom of page